Hep Email Update 2021 Top Hep Science Stories Fatty liver disease dominated the Hep science news this year, but COVID-19 remains a concern for people with liver disease. Advertisement Alaska Natives Successfully Treated With Antiviral Therapy for Hepatitis C Sofosbuvir-based regimens were well tolerated and cure rates were high in this population. You Know of Hepatitis A, B and C. Here’s HUC: Hepatitis of Unknown Cause Hepatitis of unknown cause (HUC) was the source of an outbreak linked to bottled alkaline water; 21 people got sick and one died. FDA Authorizes First Antiviral Pill for COVID-19 Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer. FDA OKs Second COVID Antiviral Pill for Limited Use Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available. The Hep Magazine Archives To read past issues of Hep, click the link! Advertisement Science News FDA OKs Second COVID Antiviral Pill for Limited Use FDA Authorizes First Antiviral Pill for COVID-19 Alaska Natives Successfully Treated With Antiviral Therapy for Hepatitis C Weight Loss Surgery Linked to Lower Risk for Liver and Heart Complications Newsfeed You Know of Hepatitis A, B and C. Here’s HUC: Hepatitis of Unknown Cause Virginia Medicaid Eases Access to Hepatitis C Treatment New Venture Offers Free and Discounted Meds for Chronic Hepatitis B New York City Opens First Supervised Injection Sites in U.S. Science News FDA OKs Second COVID Antiviral Pill for Limited Use FDA Authorizes First Antiviral Pill for COVID-19 Alaska Natives Successfully Treated With Antiviral Therapy for Hepatitis C Weight Loss Surgery Linked to Lower Risk for Liver and Heart Complications Newsfeed You Know of Hepatitis A, B and C. Here’s HUC: Hepatitis of Unknown Cause Virginia Medicaid Eases Access to Hepatitis C Treatment New Venture Offers Free and Discounted Meds for Chronic Hepatitis B New York City Opens First Supervised Injection Sites in U.S.

You are receiving this email because you opted in at one of our websites. At your request, this message was sent to newsletter@newslettercollector.com by update@hepmag.com. Please remember to add update@hepmag.com to your email address book, so that these updates aren't blocked as spam.

To change your subscription information and preferences, please visit your personal preferences page. Or you can unsubscribe completely from this list.

To forward this message, please do not use the forward button of your email application, because this message was made specifically for you only. Instead use the forward page in our newsletter system.

Did you receive this email from a friend? You can subscribe and you will receive our next newsletter directly to your inbox.

Our mailing address is: